Ms. Holly Lynn Berndt-hilu, AGCNS-BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 41792 Chesterfield Ct, Novi, MI 48375 Phone: 734-536-4233 |
Mary Smith, RN Clinical Nurse Specialist - Long-Term Care Medicare: Not Enrolled in Medicare Practice Location: 41795 W 12 Mile Rd, Novi, MI 48377 Phone: 248-449-1655 |
Jacqueline Renee Clenney, Clinical Nurse Specialist - Long-Term Care Medicare: Not Enrolled in Medicare Practice Location: 41795 W 12 Mile Rd, Novi, MI 48377 Phone: 248-449-1655 |
News Archive
With the family beach vacation right around the corner, keeping children's skin safe under the hot, summer sun should be top of mind for every parent. Recently, doctors at Nationwide Children's Hospital have seen an increase in the incidence of skin cancer cases among children ages 5-16-years-old, and particularly among teenagers. In fact, melanoma - cancer of the skin's pigment elements - is now responsible for approximately one out of 10 cancer cases in adolescents ages 15-19-years-old.
Science annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries. Respondents to the web-based survey are asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change, and a research-driven environment.
New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.
Aided in some cases by a new cast of elected officials, groups pushing for Medicaid expansion hope to reopen the debate in state legislative sessions beginning in Maine, Virginia, Louisiana, Kansas and Georgia.
Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.
› Verified 8 days ago